• 1Q24 Daxxify sales were $22.1M, -8% QoQ — due to $2.0M of redeemed coupons and normal seasonality in the aesthetics business — and +44% YoY.
• 1Q24 Daxxify volume (units shipped) was +7% QoQ.
• 1Q24 dermal-filler sales were 29.6M, -14% QoQ and -2% YoY.
• Cash at 3/31/24 was $277.1M, a $23.2M increase relative to 12/30/23 due to $94.0M of net proceeds from the Mar 2024 public offering.
• 1Q24 non-GAAP operating expenses (excluding COGS) were $68.9M, slightly below the quarterly run rate for RVNC’s full-year 2024 guidance of $290-310M.
2024 guidance
• RVNC re-iterated 2024 guidance for product revenue (Daxxify + RHA) of >=$280M.
• RVNC re-iterated 2024 guidance for non-GAAP operating expenses of $290-310M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.